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STANDFIRST 
Non-radiographic axial spondyloarthritis (nr-axSpA) and radiographic axial spondyloarthritis (r-
axSpA) are considered to represent different spectra of the same disease. Accumulating data 
suggest that the transition rate from nr-axSpA to r-axSpA in patients with early disease is low 
and identify inflammation, smoking and HLA-B27 positivity as factors associated with 
transition. 
Refers to: Dougados, M. et al. Rate and predisposing factors of sacroiliac radiographic 
progression after a 2 years follow-up period in recent onset spondyloarthritis. Arthritis 
Rheumatol. http://dx.doi.org/10.1002/art.39666 (2016). 
 Within the disease spectrum of axial spondyloarthritis (axSpA), patients are currently 
distinguished into two groups: radiographic axSpA (r-axSpA) or ankylosing spondylitis, which is 
characterized by the presence of substantial radiographic damage of the sacroiliac joints 
(fulfilling modified New York criteria for radiographic sacroiliitis); and non-radiographic axSpA 
(nr-axSpA), which is characterized by the absence of definite radiographic changes of the 
sacroiliac joints. Over time, as symptom duration increases, there is a decrease in the nr-axSpA 
to r-axSpA ratio, i.e. if subgroups of axial SpA patients with different disease durations are 
compared, subgroups with shorter disease duration are expected to have lower nr-axSpA to r-
axSpA ratios of patients than subgroups with longer disease duration, supporting the concept 
of axSpA as a single disease. Over time, a proportion of axial SpA patients might never develop 
definite radiographic damage, whereas others will experience a shift from nr-axSpA to r-
axSpA.1 The celerity of this shift and its predisposing factors are still unclear. In a newly 
published prospective study of patients with early axSpA,  Dougados et al2 report new data 
regarding the rate of transition from nr-axSpA to r-axSpA as well as factors that might be 
associated with this transition; these data have implications for both clinical practice and 
research studies.  
Patients with a high chance of progressing to r-axSpA might require different 
treatment strategies in order to prevent this irreversible change; however, there is still no 
evidence that the drugs currently available to treat axSpA3 (including NSAIDs, TNF blockers, 
and a recently approved IL-17 blocker) are actually capable of achieving this goal, and it is 
possible that this can only be achieved by drugs with different mechanisms of action: namely, 
drugs targeting bone metabolic pathways.4  
Previous studies have attempted to determine the percentage of patients who 
progress from nr-axSpA to r-axSpA over time5, 6; however, these studies had important 
methodological limitations and included a small number of patients. A third study, performed 
using the German Spondyloarthritis Inception Cohort (GESPIC), has provided the most relevant 
data so far.7 This study included 95 patients with a mean disease duration of 3.2 years and 
reported that 12% patients with nr-axSpA progressed to r-axSpA over 2 years. However, this 
finding required confirmation in other studies and in patients with a shorter disease duration.  
The new study by Dougados et al.2 determined the rate of progression from nr-axSpA 
to r-axSpA in 326 patients from the Devenir des Spondylarthopathies Indifférenciées Récentes 
(DESIR) cohort, which included patients with a mean symptom duration of 1.5 years. Only 5% 
patients progressing from nr-axSpA to r-axSpA over 2 years, which is less than half the rate 
observed in the GESPIC cohort7. If one just compares the progression rates found in these two 
studies, it could be concluded that the rate of progression from nr-axSpA to r-axSpA is lower in 
patients with a shorter disease duration. However, interpretation of these data should take 
two critical methodological issues into account.  
First, the inclusion criteria of these two studies were not the same. In the GESPIC 
cohort7, all patients with nr-axSpA had a definite clinical diagnosis of axSpA according to the 
local rheumatologist, and patients fulfilled the European Spondyloarthropathy Study Group 
(ESSG) criteria. By contrast, patients in the DESIR cohort2 had inflammatory back pain and a 
high probability (>50%) of having axSpA according to the opinion of the treating 
rheumatologist, but not all of them had definite axSpA or necessarily fulfilled axSpA criteria 
according to any classification system. Therefore, if only those patients in the DESIR cohort 
with definite axSpA had been included in the Dougados et al. study2, the observed rate of 
progression could have been increased.  
Second, in both studies, readers scored the radiographs in a random order: that is, 
without knowing their chronological order. In the GESPIC cohort7, some patients initially 
classified as r-axSpA later switched to nr-axSpA, but this regression was an uncommon event 
(2.6%). However, in the DESIR cohort2, the percentage of regressors was even higher than the 
percentage of progressors (5.7% versus 4.9%) and almost the double of the percentage of 
regressors in the GESPIC cohort (5.7% versus 2.6%). These results suggest that the known 
phenomenon of measurement error that is inherent to any type of radiographic scoring may 
have had more influence in the observed progression rate in the DESIR study2 than in the 
GESPIC study7. Such measurement error has previously been related to the moderate inter-
reader reliability when assessing radiographs of sacroiliac joints.8 In patients with rheumatoid 
arthritis, chronological reading of radiographs is preferable to random reading due to 
decreased variability when estimating progression rate, therefore increasing the efficiency of 
the reading.9 Based on these considerations, we wonder whether chronological reading would 
have been a more appropriate method to determine the progression rate from nr-axSpA to r-
axSpA in both the DESIR and GESPIC cohorts.  
Dougados et al.2 also investigated predisposing factors for radiographic progression of 
the sacroiliac joints, which they defined as progression by at least one grade in at least one 
sacroiliac joint during the 2-year follow-up period. The potential predisposing factors 
investigated in this study were: age, gender, smoking status, HLA-B27 positivity, serum C-
reactive protein (CRP) levels, MRI inflammation of the sacroiliac joints, clinical disease activity 
measured by the Bath Ankylosing Spondylitis Disease Activity Score (BASDAI) and treatment 
(NSAID and TNF-blocker therapy). Among them, the characteristics that were found to be 
independently and significantly associated with radiographic progression of the sacroiliac 
joints were: smoking at baseline (OR=3.3, 95% CI 1.0–11.5); HLA-B27 positivity (OR=12.6, 95% 
CI  (2.3–274); and a positive MRI of sacroiliac joints at baseline according to Assessment of 
Spondyloarthritis International Society (ASAS)–Outcome Measures in Rheumatology 
(OMERACT) definition (OR=48.8, 95% CI 9.3–904).  
The results of Dougados et al.2 are partially consistent with previously reported data. A 
study by Bennett et al10 found that severe sacroiliac joint inflammation on MRI and HLA-B27 
positivity were associated with the development of r-axSpA in a group of patients with 
inflammatory back pain; however, this study only included 40 patients. By contrast, no clear 
association between HLA-B27 positivity or smoking status and radiographic progression of the 
sacroiliac joints was observed in the GESPIC cohort.7 However, at the spinal level, smoking has 
been clearly associated with radiographic progression in the same cohort.1 Additionally, the 
Dougados et al.2 study did not observe an independent association with serum CRP levels, 
which were the strongest predictor of sacroiliac joint radiographic progression in the GESPIC 
cohort7. As mentioned above, these discrepancies could be explained by the differences in the 
inclusion criteria. 
Overall, we think that accumulating evidence supports the concept that nr-axSpA and 
r-axSpA are spectra of the same disease. The percentage of patients who shift from nr-axSpA 
to r-axSpA is not easy to determine, mainly due to methodological difficulties, particularly the 
variability in reading and rating radiographic changes of the sacroiliac joints. However, based 
on the data from the DESIR and GESPIC cohorts2,7, the transition rate from nr-axSpA to r-axSpA 
during the early years of the disease seems to be quite low (5–12% during 2 years of follow-
up). Furthermore, among the possible factors associated with this important shift, 
inflammation (elevated serum CRP levels or MRI inflammation of the sacroiliac joints), HLA-
B27 positivity and smoking have been identified (Figure 1). We will need to wait for studies 
with longer follow-up in order to clarify whether this low rate changes or remains stable over 
time, and also to confirm whether these characteristics are robust prognostic factors of the 
progression of structural damage of the sacroiliac joints.  
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 Figure 1. Rate of progression from non-radiographic to radiographic axial spondyloarthritis 
and predisposing factors for this shift. CRP, C-reactive protein; nr-axSpA, non-radiographic 
axial spondyloarthritis; r-axSpA, radiographic axial spondyloarthritis. Pelvic radiographs are 
shown; in the left panel the sacroiliac joints do not fulfil the radiographic criterion of the 
modified New York criteria for ankylosing spondylitis; in the right panel the sacroiliac joints 
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